April - June 2017, Volume 13, Issue 2

Botnariuc I, Ilie SM, Trifanescu OG, Bacinschi XE, Curea F, Anghel RM

Predictive Circulating Markers for Anthracycline Chemotherapy in Nonmetastatic Breast Cancer

Acta Endo (Buc) 2017, 13 (2): 209-214
doi: 10.4183/aeb.2017.209

Anthracyclines are used in breast cancer both in early and advanced stages and their recommendation together with taxanes, either concurrently or sequentially, is debatable and individualized by phenotype. Circulating biomarkers have already been introduced in clinical practice for metastatic disease monitoring. We questioned whether it might be a role for these markers in neoadjuvant and adjuvant settings too and a general review was conducted. CK18 and CTC were found predictive for anthracycline related response in preoperative setting. Soluble E-cadherin is promising, a retrospective analysis showing a direct correlation with clinical response. CEA, CA 15-3 and HER2 ECD are not of interest for their predictive role.

Keywords: breast cancer, circulating biomarkers, anthracyclines

Correspondence: Silvia Mihaela Ilie MD, “Alexandru Trestioreanu” Institute of Oncology, Ringgold Standard Institution, Dept. of Radiotherapy, 252 Fundeni Rd, Bucharest, 022328, Romania, E-mail: silviailie@gmail.com